Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. METHODS: A phase 1 clinical trial was...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: Vonderheide, Robert H, Kraynyak, Kimberly A, Shields, Anthony F, McRee, Autumn J, Johnson, Jennifer M, Sun, Weijing, Chintakuntlawar, Ashish V, Pawlicki, Jan, Sylvester, Albert J, McMullan, Trevor, Samuels, Robert, Kim, Joseph J, Weiner, David, Boyer, Jean D, Morrow, Matthew P, Humeau, Laurent, Skolnik, Jeffrey M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2021
Konular:
Clinical/Translational Cancer Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261871/
https://ncbi.nlm.nih.gov/pubmed/34230114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003019
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller